公开(公告)号：US20240076362A1

公开(公告)日：2024-03-07

申请号：US18310207

申请日：2023-05-01

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K2039/505

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20240383997A1

公开(公告)日：2024-11-21

申请号：US18621575

申请日：2024-03-29

Applicant: ALECTOR LLC

Inventor： Eric BROWN ,  Hamid SALIMI ,  Wei-Hsien HO ,  Leonard PRESTA ,  Margaret TANG ,  Jeonghoon SUN

IPC: C07K16/28 ,  A61K49/00 ,  C07K16/18 ,  G01N33/50

Abstract: Provided herein are engineered constant domains that have been engineered to comprise a blood brain barrier (BBB)-binding region, such a CDRH3 from an antibody that binds to a blood brain barrier target. Such engineered constant domains can be within a full length antibody or an antigen-binding fragment of an antibody such that the antibody or fragment is capable of binding to both the antigen of the antibody or fragment and the BBB target and is capable of being transported across the BBB.

公开(公告)号：US20210079074A1

公开(公告)日：2021-03-18

申请号：US16943123

申请日：2020-07-30

Applicant: Alector LLC

Inventor： Jeonghoon SUN ,  Wei-Hsien HO ,  Muhammad A. ALHAWAGRI ,  Philip Ling KONG ,  Herve RHINN ,  Hua LONG ,  Karpagam SRINIVASAN ,  Ananya MITRA ,  Daniel P. BERMINGHAM ,  Klaus-Dieter HEGER ,  Santiago Viveros SALAZAR ,  Francesca CIGNARELLA ,  Ilaria TASSI ,  Tina SCHWABE ,  Angie Grace YEE ,  Arnon ROSENTHAL

IPC: C07K16/18

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.